A Phase 3 interventional study of 40 mg telmisartan and 5 mg amlodipine in Hypertension, sponsored by Boehringer Ingelheim. Completed at 8 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2014-06-27.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 99 studies testing telmisartan in Hypertension — 1 open to participants now, 1 under way, none of them phase 3. Telmisartan · Hypertension.
Among the 99 studies testing telmisartan in Hypertension, this one is the 47th largest by enrollment, is the only one that started in 2011, is one of 40 in phase 3, and was the 44th registered.
6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.
Browse Hypertension studies →1 of the 99 studies testing telmisartan in Hypertension is open now, in 1 country. Recruiting first, the newest first:
Chong Kun Dang Pharmaceutical · Sites in Korea, Republic of
Ages 19–75
By country, each count listing its studies:
Telmisartan: first FDA approval 1998 (MICARDIS), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.
This study: 20 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
99 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 5 · Phase 3 40 · Phase 4 32
First in 1997; this study’s year is marked. 1 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 225 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 184 across the 99 interventional studies. Of the 91 that completed or were terminated, 14 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
75 of 99 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
122 studies in Hypertension by Boehringer Ingelheim: 1 open now, 1 under way, 1 of them phase 3. Of 120 finished, 41 (34%) have results posted.
Among the 122 studies in Hypertension by Boehringer Ingelheim, this one is the 49th largest by enrollment of the 74 interventional ones that give a count, is one of 6 that started in 2011, is one of 43 in phase 3, and was the 62nd registered.
Boehringer Ingelheim’s Hypertension studies by the year they started, since 1995.
None of the studies under way reaches primary completion within a year.
Among the 99 studies testing telmisartan in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Boehringer Ingelheim’s 122 in Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Blood pressure in hypertensive patients is rarely controlled to an optimal level by one drug alone, often a combination of two or more drugs is essential to achieve a sufficient antihypertensive effect. Therefore in Japanese Society of Hypertension (JSH) 2009 combination therapy is recommended. In JSH 2009 it is advised to start the combination therapy at a low dose, and to increase the dosage when the antihypertensive effect is not sufficient. In the Japanese long-term safety study, 259 patients received the T40/A5 mg fixed-dose combination (FDC), and after 6 weeks treatment 48 patients of them could not control their blood pressure (DBP =90) (U09-2494-01). For those patients who cannot control their blood pressure with T40/A5 mg FDC, a switch to a higher dose such as T80/A5 mg is recommended.
In the overseas 4x4 factorial design trial, a clinically meaningful difference of the blood pressure lowering effect between T80/A5 mg free combination and T40/A5 mg free combination was shown (U07-3503-02). But the sponsor has no data that verifies this difference in Japanese patients.
Thus, this clinical trial is being conducted to investigate the antihypertensive effect and safety of high dose T80/A5 mg FDC compared with low dose T40/A5 mg FDC in Japanese patients with essential hypertension. In this trial, a multi-centre, randomised, double-blind, double-dummy, active-controlled, parallel group comparison method is employed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Essential hypertensive patients
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
once daily
Drug: 5 mg amlodipine · Drug: 80 mg telmisartan
once daily
Drug: 40 mg telmisartan · Drug: 5 mg amlodipine
once daily
once daily
once daily
once daily
Reduction From the Reference Baseline in Mean Seated Diastolic Blood Pressure (DBP) at Trough
Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined At trough: 24-hour post-dosing
Time frame: Reference baseline, 8 weeks
Reduction From the Reference Baseline in Mean Seated Systolic Blood Pressure (SBP) at Trough
Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined At trough: 24-hour post-dosing
Time frame: Reference baseline, 8 weeks
Changes From the Reference Baseline in the 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Mean (Relative to Dose Time) for DBP
Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined
Time frame: Reference baseline, 8 weeks
Changes From the Reference Baseline in the 24-hour ABPM Mean (Relative to Dose Time) for SBP
Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined
Time frame: Reference baseline, 8 weeks
Changes From the Pseudo-baseline in the 24-hour ABPM Mean (Relative to Dose Time) for DBP
Pseudo-baseline: Status of patients after the 6-week open-label run-in period with telmisartan monotherapy, where patients' eligibility to enter the double-blind treatment period was examined
Time frame: Pseudo-baseline, 14 weeks
Changes From the Pseudo-baseline in the 24-hour ABPM Mean (Relative to Dose Time) for SBP
Pseudo-baseline: Status of patients after the 6-week open-label run-in period with telmisartan monotherapy, where patients' eligibility to enter the double-blind treatment period was examined
Time frame: Pseudo-baseline, 14 weeks
Changes From the Reference Baseline in DBP Hourly Mean Over the 24-hour Dosing Interval as Measured by ABPM
Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined
Time frame: Reference baseline, 8 weeks
Changes From the Reference Baseline in SBP Hourly Mean Over the 24-hour Dosing Interval as Measured by ABPM
Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined
Time frame: Reference baseline, 8 weeks
Seated DBP Control Rate at Trough
DBP control rate: The rate of patients with controlled seated DBP at trough of less than 90 mmHg after the 8-week double-blind period At trough: 24-hour post-dosing
Time frame: 8 weeks
Seated SBP Control Rate at Trough
SBP control rate: The rate of patients with controlled seated DBP at trough of less than 140 mmHg after the 8-week double-blind period At trough: 24-hour post-dosing
Time frame: 8 weeks
Seated DBP Response Rate at Trough
DBP response rate: The rate of patients who achieved an adequate response in seated DBP at trough (\<90 mmHg and/or reduction from reference baseline \>=10 mmHg) after the 8-week double-blind period At trough: 24-hour post-dosing
Time frame: 8 weeks
Seated SBP Response Rate at Trough
SBP response rate: The rate of patients who achieved an adequate response in seated SBP at trough (\<140 mmHg and/or reduction from reference baseline \>=20 mmHg) after the 8-week double-blind period At trough: 24-hour post-dosing
Time frame: 8 weeks
Seated Blood Pressure (BP) Normalisation at Trough
Seated blood pressure (BP) normalisation: The numbers of patients whose blood pressure was within normalisation criterion in terms of seated blood pressure after the 8-week double-blind period At trough: 24-hour post-dosing
Time frame: 8 weeks
| Milestone | 80 mg Telmisartan and 5 mg Amlodipine FDC | 40 mg Telmisartan and 5 mg Amlodipine FDC |
|---|---|---|
| Started | 112 | 113 |
| Completed | 111 | 111 |
| Not completed | 1 | 2 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined At trough: 24-hour post-dosing
| mm Hg | 80 mg Telmisartan and 5 mg Amlodipine FDC | 40 mg Telmisartan and 5 mg Amlodipine FDC |
|---|---|---|
| Reduction From the Reference Baseline in Mean Seated Diastolic Blood Pressure (DBP) at Trough | 4.93 ± 0.61 | 3.47 ± 0.61 |
Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined At trough: 24-hour post-dosing
| mm Hg | 80 mg Telmisartan and 5 mg Amlodipine FDC | 40 mg Telmisartan and 5 mg Amlodipine FDC |
|---|---|---|
| Reduction From the Reference Baseline in Mean Seated Systolic Blood Pressure (SBP) at Trough | 5.55 ± 0.90 | 3.41 ± 0.91 |
Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined
| mm Hg | 80 mg Telmisartan and 5 mg Amlodipine FDC | 40 mg Telmisartan and 5 mg Amlodipine FDC |
|---|---|---|
| Changes From the Reference Baseline in the 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Mean (Relative to Dose Time) for DBP | -1.54 ± 0.49 | -0.33 ± 0.49 |
Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined
| mm Hg | 80 mg Telmisartan and 5 mg Amlodipine FDC | 40 mg Telmisartan and 5 mg Amlodipine FDC |
|---|---|---|
| Changes From the Reference Baseline in the 24-hour ABPM Mean (Relative to Dose Time) for SBP | -2.81 ± 0.81 | -0.91 ± 0.82 |
Pseudo-baseline: Status of patients after the 6-week open-label run-in period with telmisartan monotherapy, where patients' eligibility to enter the double-blind treatment period was examined
| mm Hg | 80 mg Telmisartan and 5 mg Amlodipine FDC | 40 mg Telmisartan and 5 mg Amlodipine FDC |
|---|---|---|
| Changes From the Pseudo-baseline in the 24-hour ABPM Mean (Relative to Dose Time) for DBP | -12.16 ± 0.61 | -11.28 ± 0.60 |
Pseudo-baseline: Status of patients after the 6-week open-label run-in period with telmisartan monotherapy, where patients' eligibility to enter the double-blind treatment period was examined
| mm Hg | 80 mg Telmisartan and 5 mg Amlodipine FDC | 40 mg Telmisartan and 5 mg Amlodipine FDC |
|---|---|---|
| Changes From the Pseudo-baseline in the 24-hour ABPM Mean (Relative to Dose Time) for SBP | -20.96 ± 0.96 | -19.32 ± 0.95 |
Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined
| mm Hg | 80 mg Telmisartan and 5 mg Amlodipine FDC | 40 mg Telmisartan and 5 mg Amlodipine FDC |
|---|---|---|
| Hour 1 | -1.04 ± 10.27 | -0.22 ± 12.38 |
| Hour 2 | -1.95 ± 11.44 | 0.32 ± 10.93 |
| Hour 3 | -2.25 ± 11.86 | 2.87 ± 11.61 |
| Hour 4 | -3.69 ± 12.43 | -0.02 ± 10.63 |
| Hour 5 | -1.39 ± 13.22 | -0.75 ± 14.06 |
| Hour 6 | -1.58 ± 11.08 | -0.86 ± 13.32 |
| Hour 7 | -0.40 ± 12.24 | -1.25 ± 13.22 |
| Hour 8 | -1.58 ± 13.23 | 0.55 ± 13.83 |
| Hour 9 | -2.77 ± 12.83 | -0.73 ± 12.44 |
| Hour 10 | -2.80 ± 13.75 | -0.14 ± 11.58 |
| Hour 11 | -1.47 ± 11.58 | -1.16 ± 12.05 |
| Hour 12 | -0.74 ± 11.86 | -1.43 ± 13.65 |
| Hour 13 | -2.33 ± 12.96 | -1.05 ± 12.03 |
| Hour 14 | -0.53 ± 15.49 | -0.08 ± 11.36 |
| Hour 15 | -0.36 ± 13.65 | 1.86 ± 10.88 |
| Hour 16 | -0.01 ± 10.73 | 0.85 ± 10.97 |
| Hour 17 | 0.70 ± 12.16 | -0.80 ± 11.07 |
| Hour 18 | -1.89 ± 11.81 | 1.02 ± 10.33 |
| Hour 19 | -3.12 ± 12.96 | 0.10 ± 10.38 |
| Hour 20 | 0.23 ± 11.03 | -1.27 ± 11.93 |
| Hour 21 | -3.25 ± 12.85 | -0.90 ± 10.81 |
| Hour 22 | -2.00 ± 11.83 | -1.67 ± 13.14 |
| Hour 23 | -2.07 ± 12.05 | -0.53 ± 11.95 |
| Hour 24 | -0.82 ± 9.37 | 0.42 ± 11.23 |
Reference baseline: Status of patients after the 12-week open-label run-in period with telmisartan monotherapy followed by 40 mg telmisartan and 5 mg amlodipine combination therapy, where patients' eligibility to enter the double-blind treatment period was examined
| mm Hg | 80 mg Telmisartan and 5 mg Amlodipine FDC | 40 mg Telmisartan and 5 mg Amlodipine FDC |
|---|---|---|
| Hour 1 | -6.54 ± 16.03 | -1.78 ± 16.37 |
| Hour 2 | -2.78 ± 14.98 | -0.28 ± 15.82 |
| Hour 3 | -3.41 ± 16.83 | 2.72 ± 17.74 |
| Hour 4 | -4.72 ± 18.42 | -1.88 ± 17.03 |
| Hour 5 | -1.14 ± 18.23 | -2.54 ± 20.71 |
| Hour 6 | -1.68 ± 18.39 | -2.48 ± 20.01 |
| Hour 7 | -0.60 ± 19.12 | -2.45 ± 18.69 |
| Hour 8 | -2.05 ± 20.40 | -0.27 ± 22.07 |
| Hour 9 | -3.09 ± 17.35 | -1.17 ± 18.33 |
| Hour 10 | -5.78 ± 19.61 | -0.70 ± 18.91 |
| Hour 11 | -2.04 ± 19.59 | 0.69 ± 15.16 |
| Hour 12 | -4.57 ± 17.54 | 0.61 ± 16.89 |
| Hour 13 | -2.27 ± 19.90 | 0.26 ± 17.53 |
| Hour 14 | -1.46 ± 21.12 | -1.09 ± 17.49 |
| Hour 15 | -1.21 ± 17.86 | 1.41 ± 17.70 |
| Hour 16 | -0.78 ± 17.18 | 0.68 ± 15.42 |
| Hour 17 | -0.71 ± 17.58 | -1.16 ± 15.67 |
| Hour 18 | -2.66 ± 18.90 | 1.01 ± 15.84 |
| Hour 19 | -4.58 ± 18.92 | -1.24 ± 15.30 |
| Hour 20 | 0.57 ± 19.07 | -3.56 ± 17.02 |
| Hour 21 | -4.02 ± 17.27 | -1.20 ± 16.47 |
| Hour 22 | -3.88 ± 16.81 | -4.12 ± 17.40 |
| Hour 23 | -4.65 ± 21.01 | -2.71 ± 16.15 |
| Hour 24 | -2.24 ± 16.51 | 0.29 ± 16.09 |
DBP control rate: The rate of patients with controlled seated DBP at trough of less than 90 mmHg after the 8-week double-blind period At trough: 24-hour post-dosing
| percentage of participants | 80 mg Telmisartan and 5 mg Amlodipine FDC | 40 mg Telmisartan and 5 mg Amlodipine FDC |
|---|---|---|
| No | 53.1 | 60.0 |
| Yes | 46.9 | 40.0 |
SBP control rate: The rate of patients with controlled seated DBP at trough of less than 140 mmHg after the 8-week double-blind period At trough: 24-hour post-dosing
| percentage of participants | 80 mg Telmisartan and 5 mg Amlodipine FDC | 40 mg Telmisartan and 5 mg Amlodipine FDC |
|---|---|---|
| No | 55.2 | 55.3 |
| Yes | 44.8 | 44.7 |
DBP response rate: The rate of patients who achieved an adequate response in seated DBP at trough (\<90 mmHg and/or reduction from reference baseline \>=10 mmHg) after the 8-week double-blind period At trough: 24-hour post-dosing
| percentage of participants | 80 mg Telmisartan and 5 mg Amlodipine FDC | 40 mg Telmisartan and 5 mg Amlodipine FDC |
|---|---|---|
| No | 29.5 | 32.1 |
| Yes | 70.5 | 67.9 |
SBP response rate: The rate of patients who achieved an adequate response in seated SBP at trough (\<140 mmHg and/or reduction from reference baseline \>=20 mmHg) after the 8-week double-blind period At trough: 24-hour post-dosing
| percentage of participants | 80 mg Telmisartan and 5 mg Amlodipine FDC | 40 mg Telmisartan and 5 mg Amlodipine FDC |
|---|---|---|
| No | 19.6 | 17.9 |
| Yes | 80.4 | 82.1 |
Seated blood pressure (BP) normalisation: The numbers of patients whose blood pressure was within normalisation criterion in terms of seated blood pressure after the 8-week double-blind period At trough: 24-hour post-dosing
| participants | 80 mg Telmisartan and 5 mg Amlodipine FDC | 40 mg Telmisartan and 5 mg Amlodipine FDC |
|---|---|---|
| No | 41 | 44 |
| Optimal | 21 | 13 |
| Normal | 23 | 26 |
| High-normal | 27 | 29 |
Collected over From first drug administration in the double-blind treatment period until 24 hours after the last dose, up to 69 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 80 mg Telmisartan and 5 mg Amlodipine FDC | — | 1/112 (0.9%) | 6/112 (5.4%) |
| 40 mg Telmisartan and 5 mg Amlodipine FDC | — | 1/113 (0.9%) | 6/113 (5.3%) |
| Event | 80 mg Telmisartan and 5 mg Amlodipine FDC | 40 mg Telmisartan and 5 mg Amlodipine FDC |
|---|---|---|
| Cerebral artery occlusionNervous system disorders | 1/112 | 0/113 |
| Clavicle fractureInjury, poisoning and procedural complications | 0/112 | 1/113 |
| Event | 80 mg Telmisartan and 5 mg Amlodipine FDC | 40 mg Telmisartan and 5 mg Amlodipine FDC |
|---|---|---|
| NasopharyngitisInfections and infestations | 6/112 | 6/113 |
| Age, Continuous(year) | 80 mg Telmisartan and 5 mg Amlodipine FDC | 40 mg Telmisartan and 5 mg Amlodipine FDC | Total |
|---|---|---|---|
| Mean | 54.6 ± 8.4 | 52.8 ± 9.4 | 53.7 ± 8.9 |
| Sex: Female, Male(Participants) | 80 mg Telmisartan and 5 mg Amlodipine FDC | 40 mg Telmisartan and 5 mg Amlodipine FDC | Total |
|---|---|---|---|
| Female | 23 | 24 | 47 |
| Male | 89 | 89 | 178 |
The record gives a start of Jan 2011 and a primary completion of Sep 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2012, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Telmisartan